Gustave Roussy Foundation - CRIS cancer Foundation
Clinical Scientist Emerging Leader Programme
Introduction
Calling for applications to the GRF-CRIS Clinical Scientist Emerging Leader Programme, CRIS Cancer Foundation and Gustave Roussy Foundation are partnering to offer an exciting opportunity for a talented early career clinician scientist to develop their academic skills and expertise, placing them on a firm footing for a career as an independent clinical academic.
Candidates must be specialist clinicians, young investigators with some research experience and with the potential to develop transformative research and high potential for setting their team at Gustave Roussy Institute when finishing this Programme.
The aim of the GRF-CRIS Clinical Scientist Emerging Leader Programme is to provide competitive financial conditions and incentives for the early career of talented emerging young clinician scientists to lead projects, developing their research skills, academic skills, expertise and leadership on all types of cancer pathologies at the Gustave Roussy Institute.
This unique opportunity provides a pathway towards independence whilst facilitating collaborative research which ultimately translates to patient benefit.
Call for Applications
Gustave Roussy Foundation and CRIS Cancer run the GRF-CRIS Clinical Scientist Emerging Leader Programme call, to award 1 research grant, covering a three-year period, for the purposes of incentive clinical scientists to develop their career at the Gustave Roussy Institute.
The call for applications opens on 15th April 2026 and closes on 16th June 2026 at 15pm (Central European Time - CET).
Beneficiaries can take up their position at the host institution as soon as the resolution of the call is published. In duly justified cases of force majeure, this start date may be postponed, subject to individual assessment by CRIS and GRF. The start date must be communicated to the Gustave Roussy Foundation and CRIS Cancer Foundation prior to that date.
All applications must be submitted by email to RLtrials@gustaveroussy.fr and convocatorias@criscancer.org during the application submission period for the 2026 call for applications.
Related documents:
